Latest News and Press Releases

Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference